Helix BioPharma (TSE:HBP) Share Price Passes Below 50 Day Moving Average - What's Next?

Key Points

• Shares fell below their 50-day moving average: Helix BioPharma traded down to C$1.89—matching its 50-day SMA—and last traded at C$1.89 on very light volume (110 shares).
• Weak liquidity and leveraged balance sheet: The company shows a very low current ratio (0.04), high debt-to-equity (2.34), a negative P/E (-31.50) and a market cap of C$144.35 million, with the 200-day SMA at C$2.09.
• Clinical-stage oncology pipeline: Helix is developing L-DOS47, an antibody-enzyme conjugate that completed Phase Ib in NSCLC and targets CEACAM6, alongside next-generation bi-specific ADCs in discovery.

Helix BioPharma Corp. (TSE:HBP - ) shares crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$1.89 and traded as low as C$1.89. Helix BioPharma shares last traded at C$1.89, with a volume of 110 shares.

Helix BioPharma Price Performance

The company has a current ratio of 0.04, a quick ratio of 1.04 and a debt-to-equity ratio of 2.34. The business has a fifty day simple moving average of C$1.89 and a 200 day simple moving average of C$2.09. The stock has a market capitalization of C$144.35 million, a P/E ratio of -31.50 and a beta of 0.38.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.